T2 Biosystems. has filed a patent for methods, panels, cartridges, and systems to detect pathogens and diagnose diseases like bacteremia and sepsis. The claim details have been canceled. GlobalData’s report on T2 Biosystems gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on T2 Biosystems, MRI calibration techniques was a key innovation area identified from patents. T2 Biosystems's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Pathogen detection methods, panels, cartridges, and systems
A recently filed patent (Publication Number: US20240026415A1) describes a method for detecting the presence of a specific species in a liquid sample. The method involves amplifying target nucleic acids characteristic of the species in the sample to form amplicons, adding magnetic particles with binding moieties to the sample, and exposing the mixture to a bias magnetic field and RF pulse sequence in a detection tube within a device. The signal produced is then measured to determine the presence of the species based on the result. The patent claims cover various aspects of the method, including the use of specific primer pairs, magnetic particles conjugated to probes, and the ability to detect microbial species at low concentrations in different types of liquid samples.
Furthermore, the patent also includes methods for diagnosing and treating bloodstream infections or sepsis in subjects by detecting the presence of microbial species in liquid samples using the described method. The presence of a microbial species in the sample can help identify individuals who may have a bloodstream infection or sepsis, allowing for timely administration of appropriate therapy. The patent specifies the use of the method for diagnosing bacteremia in humans, highlighting its potential application in clinical settings for the detection and treatment of serious infections. Overall, the patent outlines a comprehensive approach for detecting, diagnosing, and treating microbial infections using a novel method based on nucleic acid amplification and magnetic particle technology.
To know more about GlobalData’s detailed insights on T2 Biosystems, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
